Biotech
Ottimo Pharma
Ottimo Pharma raises $140M Series A at $600M valuation
San Francisco, CADecember 19, 20241 min read
Total Raised
$140M
Valuation
$600M
Latest Round
Series A
Employees
60+
Ottimo Pharma: Series A Funding Round
Ottimo Pharma has successfully raised $140M in Series A funding, reaching a valuation of $600M.
Company Overview
Developing biosimilar cancer treatment to compete with Keytruda
Funding Details
The Series A round was led by OrbiMed, with participation from Avoro Capital.
Company Information
- Headquarters: San Francisco, CA
- Founded: 2024
- Employees: 60+
- Category: Biotech
Investment
Ottimo Pharma plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- OrbiMed: Verified investor in Series A
- Avoro Capital: Verified investor in Series A
Company Info
Headquarters
San Francisco, CA
Founded
2024
Team Size
60+
Last Round
$140M(Dec 2024)
Investors (2)
O
OrbiMedLeadLead Investor
Verified investor in Series A
A
Avoro CapitalInvestor
Verified investor in Series A
Share
Related Reports
Biotech
AusperBio
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
David Chen
Dec 30, 2025
0 min read•$73M Series B
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free